Preterm labor: current pharmacotherapy options for tocolysis
Date
2014
Authors
van Vliet, E.O.G.
Boormans, E.M.
de Lange, T.S.
Mol, B.W.
Oudijk, M.A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Expert Opinion on Pharmacotherapy, 2014; 15(6):787-797
Statement of Responsibility
Elvira OG van Vliet, Elisabeth M Boormans, Thomas S de Lange, Ben W Mol and Martijn A Oudijk
Conference Name
Abstract
INTRODUCTION: In the developed world, preterm birth is in quantity and in severity the most important issue in obstetric care. Adverse neonatal outcome is strongly related to gestational age at delivery. Since the pathophysiological mechanism of preterm birth is not yet completely unraveled, the development of successful preventive strategies is hampered. When preterm labor is actually threatening, current pharmacological therapies focus on inhibition of preterm contractions. This allows for transportation of the mother to a center with a neonatal intensive care unit and administration of corticosteroids to enhance fetal lung maturation. Globally, however, large practice variation exists. AREAS COVERED: The aim of this review is to provide an overview of current pharmacological therapies for preterm labor. EXPERT OPINION: For the initial tocolysis, the use of atosiban or nifedipine for 48 h is recommended based on the largest effectiveness and most favorable side effect profile. However, since data that convincingly indicate the beneficial effect of tocolytics on neonatal outcome are lacking, it might well be that tocolytics are ineffective. The role of progesterone in treatment of acute tocolysis is limited, but it might play a role in the prevention of preterm labor or as sensitizer for other tocolytic agents.
School/Discipline
Dissertation Note
Provenance
Description
Published online: 17 Feb 2014
Access Status
Rights
© 2014 Informa UK, Ltd.